Assess whether RWE can replace or only supplement an RCT (2af61a)

Situation

A boxed-warning proposal from the review division put complete-response-letter deficiency list in front of pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / FDA Response and Labeling close is RWE can replace or from complete-response-letter deficiency list, and the live options are RWE can replace, Only supplement an RCT.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose RWE can replace / Only supplement an RCT using complete-response-letter deficiency list after a boxed-warning proposal from the review division.

Hypotheses to test

• The population in complete-response-letter deficiency list is the one a boxed-warning proposal from the review division named, so RWE can replace follows for this FDA Response and Labeling file.
• The population in complete-response-letter deficiency list is adjacent only to a boxed-warning proposal from the review division; Only supplement an RCT is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a boxed-warning proposal from the review division before complete-response-letter deficiency list arrived; no new FDA Response and Labeling path.
• Provenance on complete-response-letter deficiency list after a boxed-warning proposal from the review division is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether complete-response-letter deficiency list supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a boxed-warning proposal from the review division and write the one fact that would move RWE can replace or for pharmacovigilance medical reviewer.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a boxed-warning proposal from the review division). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.